These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29498535)

  • 21. Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis.
    Metzger JC; Wollschläger D; Miederer M; Vaupel P; Moehler M; Schmidberger H; Mayer A
    Strahlenther Onkol; 2017 Oct; 193(10):791-799. PubMed ID: 28770295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
    Tandberg DJ; Cui Y; Rushing CN; Hong JC; Ackerson BG; Marin D; Zhang X; Czito BG; Willett CW; Palta M
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1002-1007. PubMed ID: 30055238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.
    van Rossum PS; van Lier AL; van Vulpen M; Reerink O; Lagendijk JJ; Lin SH; van Hillegersberg R; Ruurda JP; Meijer GJ; Lips IM
    Radiother Oncol; 2015 May; 115(2):163-70. PubMed ID: 26002307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
    Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
    J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.
    Goense L; Heethuis SE; van Rossum PSN; Voncken FEM; Lagendijk JJW; Lam MGEH; Terhaard CH; van Hillegersberg R; Ruurda JP; Mook S; van Lier ALHMW; Lin SH; Meijer GJ
    Nucl Med Commun; 2018 Jan; 39(1):60-67. PubMed ID: 29023336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient perspectives on repeated contrast-enhanced mammography and magnetic resonance during neoadjuvant chemotherapy of breast cancer.
    Pires-Gonçalves L; Henriques Abreu M; Ferrão A; Guimarães Dos Santos A; Aguiar AT; Gouvêa M; Henrique R
    Acta Radiol; 2023 May; 64(5):1816-1822. PubMed ID: 36575580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor volume regression during neoadjuvant chemoradiotherapy for esophageal cancer: a prospective study with weekly MRI.
    Defize IL; Boekhoff MR; Borggreve AS; van Lier ALHMW; Takahashi N; Haj Mohammad N; Ruurda JP; van Hillegersberg R; Mook S; Meijer GJ
    Acta Oncol; 2020 Jul; 59(7):753-759. PubMed ID: 32400242
    [No Abstract]   [Full Text] [Related]  

  • 29. The benefit of PET/CT in the diagnosis and treatment of esophageal cancer.
    Vomackova K; Neoral C; Aujeský R; Vrba R; Stasek M; Myslivecek M; Formánek R
    Rozhl Chir; 2015 Jan; 94(1):8-16. PubMed ID: 25604979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using
    Goense L; Ruurda JP; Carter BW; Fang P; Ho L; Meijer GJ; van Hillegersberg R; Hofstetter WL; Lin SH
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1742-1751. PubMed ID: 29663014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade.
    Djuric-Stefanovic A; Micev M; Stojanovic-Rundic S; Pesko P; Saranovic Dj
    Eur J Radiol; 2015 Dec; 84(12):2477-84. PubMed ID: 26467704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. International survey on esophageal cancer: part II staging and neoadjuvant therapy.
    Boone J; Livestro DP; Elias SG; Borel Rinkes IH; van Hillegersberg R
    Dis Esophagus; 2009; 22(3):203-10. PubMed ID: 19191855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival.
    Hegemann NS; Koepple R; Walter F; Boeckle D; Fendler WP; Angele MK; Boeck S; Belka C; Roeder F
    Strahlenther Onkol; 2018 May; 194(5):435-443. PubMed ID: 29349603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multimodal imaging of esophagus and cardia cancer before and after treatment.
    Fiore D; Baggio V; Ruol A; Bocus P; Casara D; Corti L; Muzzio PC
    Radiol Med; 2006 Sep; 111(6):804-17. PubMed ID: 16896560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis.
    de Gouw DJJM; Klarenbeek BR; Driessen M; Bouwense SAW; van Workum F; Fütterer JJ; Rovers MM; Ten Broek RPG; Rosman C
    J Thorac Oncol; 2019 Jul; 14(7):1156-1171. PubMed ID: 30999111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
    Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
    Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prediction of pathologic complete response in esophageal cancer after neoadjuvant radiochemotherapy using FDG-PET/CT and diffusion-weighted MRI].
    Hecht M; Semrau S
    Strahlenther Onkol; 2021 Sep; 197(9):862-864. PubMed ID: 34279687
    [No Abstract]   [Full Text] [Related]  

  • 38. 18F FDG-PET/CT evaluation of histological response after neoadjuvant treatment in patients with cancer of the esophagus or gastroesophageal junction.
    Gabrielson S; Sanchez-Crespo A; Klevebro F; Axelsson R; Albert Tsai J; Johansson O; Nilsson M
    Acta Radiol; 2019 May; 60(5):578-585. PubMed ID: 30111193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
    Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
    Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
    Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.